Trial reportBMC oral health2025
Efficacy of photobiomodulation therapy using 980 nm versus 635 nm diode lasers for treatment of myofascial pain : a randomized controlled trial.
Trial report in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07069764 (Efficacy of Photobiomodulation Therapy Using 980nm Versus 635nm Diode Lasers for Treatment of Myofascial Pain), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Photobiomodulation Therapy Using 980nm Versus 635nm Diode Lasers for Treatment of Myofascial Pain
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyofascial pain syndrome (MPS) is a common musculoskeletal disorder characterized by myofascial trigger points and muscle dysfunction. Photobiomodulation therapy (PBMT) with diode lasers has shown promise for analgesia and functional improvement in MPS management.
aimThis study compared the efficacy of 635 nm and 980 nm diode lasers in alleviating pain and enhancing mandibular function in MPS patients.
methodsThirty patients were randomized into two groups Group A (635 nm, 0.5 W, 60 s, 38.2 J/cm²) and Group B (980 nm, 0.2 W, 60 s, 15.3 J/cm²), applied twice weekly for five weeks. Outcomes included visual analogue scale (VAS), Maximum Mouth Opening (MMO), lateral/protrusive movements (LM/PM), and surface electromyography (sEMG) at baseline, post-treatment, and one-month follow-up.
resultsBoth groups showed significant improvements in all outcome measures (p < 0.001). VAS decreased from 7.6 ± 1.2 to 2.9 ± 1.3 (≈ 62% reduction) in the 635 nm group, and from 7.8 ± 1.1 to 2.1 ± 0.9 (≈ 73% reduction) in the 980 nm group (between-group p = 0.02). Maximum Mouth Opening (MMO) increased by 7.6 mm (34.5 ± 4.2 → 42.1 ± 3.2) in the 635 nm group versus 10.2 mm (34.0 ± 3.9 → 44.2 ± 2.9) in the 980 nm group (p = 0.01). Lateral movement (LM) improved by 2.3 mm vs. 2.8 mm, and Protrusive movement (PM) improved by 1.7 mm vs. 2.1 mm in the 635 nm and 980 nm groups, respectively. sEMG showed greater muscle activity reduction with 980 nm vs. 635 nm (Masseter: 47–51% vs. 39–40%; Temporalis: 43–44% vs. 36%; see(Table 3 for full data).
conclusionPBMT with 980 nm produced superior pain relief, muscle relaxation, and Mandibular function recovery compared to 635 nm, likely due to deeper tissue penetration. However, interpretation should consider the small sample size and lack of placebo control.
trial registrationClinicalTrials.gov, NCT07069764. Registered retrospectively on 07 July 2025.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.